This month NETRF CEO Elyse Gellerman presented on behalf of INCA at the ASCO Quality Care Symposium in Boston. NETRF is a member of INCA,
By Anne-Marie Green Director of Communications, NETRF Erik Mittra, MD, PhD, is the Section Chief of Molecular Imaging and Therapy at Oregon Health & Science
Every Sunday, members of Brandon Raabe’s family log on to Google Meet from across the country. They trade ideas, divide up tasks, and plan a
By Anna C. Greene, PhD, NETRF Chief Scientific Officer Research is helping physicians make more informed decisions about how to treat and monitor neuroendocrine cancers.
By Anna C. Greene, PhD, NETRF Chief Scientific Officer Scientific progress rarely comes from a single experiment, or even a single research grant. It happens
When chemotherapy stops working, patients and their care teams are left with few options. For people with poorly differentiated neuroendocrine carcinoma, that moment comes too
By Anne-Marie Green Director of Communications, NETRF Based in Columbus, Ohio, Tawnisha Jones has spent 11 years as a senior outpatient coder at the Ohio
Elyse Gellerman, MHS, NETRF CEO When neuroendocrine cancer advocates from around the world gather, there’s tremendous energy and commitment to serving the needs of patients
By Anna C. Greene, PhD, NETRF Chief Scientific Officer The language used to describe neuroendocrine cancer is complex, and it is not always used consistently.
By Anna C. Greene, PhD, NETRF Chief Scientific Officer People with neuroendocrine tumors (NETs) often ask why the same treatment can work very well for